Founded in 2001, Cell>Point is a privately held biopharmaceutical company that is developing novel intra-nuclear universal molecular imaging and therapeutic products for the diagnosis, staging, treatment and post therapy assessment of cancer, cardiovascular diseases and infectious diseases using platform technologies licensed from The Board of Regents of The University of Texas System (“UT”) and M.D. Anderson Cancer Center (“M.D. Anderson”), Houston, Texas.
